Fluorescent Immunolabelling for endogenous ChAT in mice striatum
By onThis immunohistochemistry protocol has been designed and adjusted specifically for ChAT immunolabelling in the mice striatum.
Immunofluorescent labeling of cultured cells
By onThis protocol describes the process of Paraformaldehyde fixation and immunofluorescent-labeling of cultured cells.
Electrophysiological recording from a chronic chamber-implanted non-human primate
By onThis protocol describes the preparation and insertion of extracellular recording electrodes into intracranial targets of a non-human primate implanted with a chronic recording chamber.
Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics
By onA detailed multiscale model of mouse primary motor cortex accurately predicted responses to behavioral states and manipulations, aiding in understanding cortical function at different scales.
Genotyping mice from ear clips
By onThis protocol describes the genotyping procedure from ear clip samples. This includes a general PCR protocol for primers with annealing temperatures in the range 55-70 degrees C. For other primers, the thermal cycling should be adjusted.
Tail suspension test to assess depression/anxiety behavior in parkinsonian mice
By onThe Tail Suspension Test is a mouse behavioral paradigm measuring behavioral despair or “depression-like” behavior and learned helplessness.
Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s
By onThis data show that LTCC function in DA axons, and isradipine effect, are locally governed and suggest they vary in a manner that in turn might impact on, or reflect, the cellular stress that leads to parkinsonian degeneration.
Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms
By onA study on Parkinson's disease links gut microbiome to brain health. Analysis of 490 PD patients and 234 controls reveals dysbiosis, microbial clusters, and disease-promoting factors in PD microbiome, offering insights for future research.
In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson’s disease
By onUsing a newly developed rodent model, the authors assessed whether the intracellular buildup of neuromelanin that occurs with age can be slowed down in vivo to prevent or attenuate Parkinson’s disease.
Immunohistochemistry Protocol – Chu lab (Wichman)
By onThis protocol describes immunohistochemistry.
Rotarod Test to assess motor coordination in a mouse parkinsonian model
By onThis protocol evaluates motor coordination in the rotarod assay in parkinsonian mice.
Custom open-chamber microfluidic fabrication
By onThis protocol described the fabrication of two- and three-open chambered microfluidics suitable for cell culturing using commercially acquired master mould.
Peripheral neuronal activation shapes the microbiome and alters gut physiology
By onThe authors specifically activate ChAT- or TH-expressing gut-associated neurons in mice and perform multi-omics, finding that subsets of peripherally-activated neurons differentially regulate the gut microbiome and host GI physiology.
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?
By onWith over 15 FDA approved drugs on the market and numerous ongoing clinical trials, RNA therapeutics, such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have shown great potential to treat human disease. Their mechanism of action is based entirely on the sequence of validated disease-causing genes without the prerequisite knowledge of protein structure, activity or cellular location. In contrast to small molecule therapeutics that passively diffuse across the cell membrane's lipid bilayer, RNA therapeutics are too large, too charged, and/or too hydrophilic to passively diffuse across the cellular membrane and instead are taken up into cells by endocytosis. However, endosomes are also composed of a lipid bilayer barrier that results in endosomal capture and retention of 99% of RNA therapeutics with 1% or less entering the cytoplasm. Although this very low level of endosomal escape has proven sufficient for liver and some CNS disorders, it is insufficient for the vast majority of extra-hepatic diseases. Unfortunately, there are currently no acceptable solutions to the endosomal escape problem. Consequently, before RNA therapeutics can be used to treat widespread human disease, the rate-limiting delivery problem of endosomal escape must be solved in a nontoxic manner.
Immunohistochemistry for Carbon Fiber Thread Electrodes
By onMethods for immunofluorescent staining of brain tissue with indwelling electrodes.
